Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to

First Page		Document Content
Date: 2016-07-29 19:00:51		Intersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients with Chronic Sinus Disease MENLO PARK, Calif.—Aug. 1, 2016—Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to Add to Reading List Source URL: propelopens.com Download Document from Source Website File Size: 29,02 KB Share Document on Facebook